The Future Role of Anti-Tumour Necrosis Factor (TNF) Products in the Treatment of Rheumatoid Arthritis

This publication has 40 references indexed in Scilit:

• Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein
  New England Journal of Medicine, 1997
• Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells.
  1997
• Role of tumor necrosis factor‐α and platelet‐activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis
  European Journal of Immunology, 1996
• Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures.
  Journal of Clinical Investigation, 1996
• ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
  Annual Review of Immunology, 1996
• In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
  The Journal of Immunology, 1996
• Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?
  Annals of the Rheumatic Diseases, 1993
• Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule
  Science, 1992
• Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.
  Annals of the Rheumatic Diseases, 1990
• Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts.
  Journal of Experimental Medicine, 1985